2 results
Approved WMOPending
The primary objective of the study is to assess the pharmacokinetics (PK) of PXL770 in AMN subjects at the dose of 500mg once daily (OD) and 250mg twice daily (BID) after 4 weeks of treatment.
Approved WMOPending
To assess the safety and effectiveness of enVast coronary thrombectomy system thrombectomy as an adjunctive measure to conventional intervention as compared to conventional intervention in ST-segment elevation myocardial infarction (STEMI) patients…